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Background. Clinicians have limited therapeutic options for enteric as a result of increasing antimicrobial resistance, and there-
fore typhoid vaccination is recommended as a preventive measure. As a part of the Surveillance for Enteric Fever in Asia Project 
(SEAP), we  investigated the extent measured the burden of antimicrobial resistance (AMR) among confirmed enteric fever cases in 
Bangladesh, Nepal, and Pakistan. 
Methods. From September 2016–September 2019, SEAP recruited study participants of all age groups from its outpatient, in-
patient, hospital laboratory, laboratory network, and surgical sites who had a diagnosis of febrile illness that was either suspected or 
blood culture confirmed for enteric fever. Antimicrobial resistance of isolates was determined by disc diffusion using Clinical and 
Laboratory Standard Institute cut-off points. We reported the frequency of multidrug resistance (MDR)(resistance to ampicillin, 
cotrimoxazole, and chloramphenicol), extensive drug resistance (XDR) (MDR plus non-susceptible to fluoroquinolone and any 3rd 
generation cephalosporins), and fluoroquinolone (FQ) and azithromycin non-susceptibility. 
Results. We enrolled 8,705 blood culture confirmed enteric fever cases: 4,873 (56%) from Bangladesh, 1,602 (18%) from Nepal and 
2,230 (26%) from Pakistan. Of these, 7,591 (87%) were Salmonella Typhi and 1114 (13%) were S. Paratyphi. MDR S. Typhi was identified 
in 17% (701/4065) of isolates in Bangladesh, and 1% (19/1342) in Nepal. In Pakistan, 16 % (331/2084) of S. Typhi isolates were MDR, and 
64% (1319/2074) were XDR. FQ nonsusceptibility among S. Typhi isolates was 98% in Bangladesh, 87% in Nepal, and 95% in Pakistan. 
Azithromycin non-susceptibility was detected in 77 (2%) in Bangladesh, 9 (.67%) in Nepal and 9 (.59%) isolates in Pakistan. In Pakistan, 
three (2%) S. Paratyphi isolates were MDR; no MDR S. Paratyphi was reported from Bangladesh or Nepal. 
Conclusions. Although AMR against S. Paratyphi was low across the three countries, there was widespread drug resistance among S. 
Typhi, including FQ non-susceptibility and the emergence of XDR S. Typhi in Pakistan, limiting treatment options. As typhoid conjugate 
vaccine (TCV) is rolled out, surveillance  should continue to monitor changes in AMR to inform policies and to monitor drug resistance 
in S. Paratyphi, for which there is no vaccine.
Keywords.  enteric fever; antimicrobial resistance; multidrug resistance; extensive drug resistance; Asia.
Enteric fever, caused by Salmonella enterica serovar Typhi (S. Typhi) 
and Salmonella enterica serovar Paratyphi (S. Paratyphi) remains a 
major public health problem in many parts of Asia and Africa, com-
monly occurring in pediatric populations [1–3]. It is an acute sys-
temic infectious disease that was responsible for an estimated 14.3 
million cases of typhoid and paratyphoid fever and 135.9 thousand 
deaths globally in 2017 [4]. Multidrug resistance (MDR) and fluor-
oquinolone (FQ) non-susceptibility are increasingly reported for S. 
Typhi and S. Paratyphi in South Asia and Africa [5–8].
Surveillance studies demonstrate considerable geographic 
variation in the proportion of S. Typhi isolates that are MDR 
within the same region, with sites in Nepal, India, Pakistan, and 
Vietnam having higher rates of MDR than sites in China and 
Indonesia [1, 9]. A declining trend of MDR typhoid in South 
Asia has been reported, with the exception of Pakistan, where 
drug resistance continues to be high [10]. In Bangladesh, a de-
cline in the isolation rate of MDR strains was reported between 
2004–2016 [11], with a similar observation being reported from 
India and Nepal [12–16]. Some suggest that with a significant 
decrease in MDR strains, cheaper and more effective first-line 
antibiotics may re-emerge as drugs of choice for the treatment 
of typhoid fever in these countries [12], although this idea 
needs to be evaluated in clinical practice before any change in 
treatment recommendations are proposed. Outbreaks of MDR 
strains in Nepal and Bangladesh have led to the widespread use 
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isolates have been non-susceptible to fluoroquinolones in most 
Asian countries, including Bangladesh, Nepal, and Pakistan for 
the last several years [6, 18–20]. Growing non-susceptibility to 
antibiotics, especially ceftriaxone and FQ, severely limits the 
treatment options.
The emergence of extensively drug resistant (XDR) 
S. Typhi is an added threat in the face of ongoing high 
rates of non-susceptibility to other antimicrobials. Drug- 
non-susceptibility is not only associated with severity of ill-
ness, but it also increases the length of stay in the hospital and 
the cost of treatment, and it can result in higher morbidity 
and mortality [21]. The situation is particularly worrisome in 
resource-limited settings where the burden of disease is high and 
the few remaining effective antimicrobials are either unavailable 
or too expensive for public health services or the general public 
[22]. Diagnosis of typhoid, in endemic countries, as shown in a 
recent report from Nepal, depends on physicians’ clinical judg-
ment [23]. The probability of sending a blood culture for diag-
nosis depends on multiple factors: duration of fever, presence 
or absence of signs and symptoms of other diseases, and prior 
antibiotic use. These factors, coupled with limited availability of 
facilities for blood culture, leads to underreporting of the true 
number of cases of blood culture-confirmed typhoid [24, 25].
While enteric fever is endemic in South Asia, reliable 
population-based antimicrobial resistance surveillance data 
are lacking. The Surveillance for Enteric Fever in Asia Project 
(SEAP) was a large, multi-center, prospective surveillance 
study capturing data on the burden of enteric fever and the anti-
microbial susceptibility of the isolates. From 2016 to 2019, SEAP 
used a uniform methodology to enroll patients with culture-
confirmed enteric fever at participating sites in Bangladesh, 
Nepal, and Pakistan, to record laboratory data, clinical meta-
data and patient outcomes.
The objective of this study was to measure the burden of anti-
microbial resistance (AMR) in S. Typhi and S. Paratyphi isolates 
among patients with enteric fever in Bangladesh, Nepal, and 
Pakistan. The results from this study will contribute  important 
data on AMR for comparison across and within these coun-
tries. Additionally, the data can be used as an important base-
line measurement of AMR before the introduction of typhoid 
conjugate vaccine (TCV) into routine immunization programs 
in these three countries.
METHODS
Study Design, Sites and Participants
This prospective surveillance study was conducted at hospitals 
and laboratory networks in Bangladesh, Nepal and Pakistan. 
The study recruited cases from Dhaka Shishu (Children’s) 
Hospital and Shishu Sasthya (Pediatric) Foundation Hospital 
in Bangladesh; Dhulikhel Hospital and Kathmandu Medical 
College and Teaching Hospital in Nepal; and the Aga Khan 
University Hospital (AKUH), Kharadar General Hospital 
(KGH), Jinnah Postgraduate Medical Center (JPMC) and the 
National Institute of Child Health (NICH) in Pakistan. Cases 
were also recruited from the laboratory networks,  including 
the Popular Diagnostic Centers (Dhanmondi, Mirpur, and 
Shamoly branches), Bangladesh; the Alka Hospital, Nepal 
Medical College, Kathmandu Model Hospital, Bir Hospital, 
Helping Hands Clinic, Nepal Police Hospital, Kanti Children 
Hospital, and Nepal Army Hospital, Nepal; and the Aga Khan 
University Laboratory Network and AKUH main laboratory 
collection unit, Pakistan.
Case Definition and Enrollment Criteria
Study participants included individuals of all age groups at 
outpatient, inpatient, hospital laboratory, laboratory network 
and surgical sites, with a diagnosis of febrile illness that was 
either suspected or blood culture-confirmed for enteric fever. 
Outpatients from a defined catchment area [26] with fever for 
≥3 days in the last 7 days and advised blood culture were en-
rolled into the study. For inpatients, all suspected or culture-
confirmed cases were enrolled. Patients from the hospital 
laboratories and laboratory network sites were identified from 
lab reports; if their blood culture was positive for S. Typhi or S. 
Paratyphi they were contacted by telephone and enrolled in the 
study.
Laboratory Samples and Analysis
A trained phlebotomist at designated SEAP sites collected a 
blood sample immediately after the participant  was enrolled 
and before antibiotic administration. Samples were incubated 
overnight at 37°C. Blood culture bottles were processed on BD 
Bactec automated blood culture system. Gram stain and sub-
sequent subcultures were performed on Sheep Blood Agar, 
MacConkey’s Agar, and Chocolate Agar from samples positive 
by Bactec. Positive cultures suggestive of S. Paratyphi and S. 
Typhi were confirmed serologically with BD Difco™ Salmonella 
O Antiserum Factor 9, Antiserum Vi, and Antiserum Factor 
2 antisera. All isolates were tested for their susceptibility as 
per Clinical and Laboratory Standard Institute Guidelines-
M100-ED-29, 2019. Isolates were multidrug resistant (MDR) 
if they were resistant to ampicillin/amoxicillin, chloramphen-
icol, and trimethoprim-sulfamethoxazole. Isolates were fluor-
oquinolone (FQ) non-susceptible if they had intermediate 
susceptibility or were non-susceptible to ciprofloxacin and were 
extensively drug resistant (XDR) if they were MDR and were 
also non-susceptible to fluoroquinolone and any 3rd generation 
cephalosporins.
Data Collection and Analysis
Trained research associates with a nursing or medical back-
ground interviewed the patients or their caretakers to collect 
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We reviewed medical charts and files to gather data on clin-
ical and laboratory testing and diagnosis of any complications. 
Data were entered on tablets using electronic case report forms. 
Descriptive analyses such as AMR by age, gender, recruitment 
areas, countries and months were performed. Complications 
such as hepatitis, hemodynamic shock, pulmonary complica-
tions, gastrointestinal complications and sepsis were compared 
between MDR/XDR S. Typhi and non-MDR/XDR typhoid pa-
tients using Fisher’s Exact test [18].
Ethical Considerations
Written informed consent was obtained from adults (18+ 
years) and parents or legal guardians for children; assent 
along with parental consent was taken for children 15 to 
17  years old. Participants could withdraw consent at any 
time. A  unique identifier, with no personal identifying de-
tails, was assigned to maintain confidentiality. All consent/
assent forms, signatures, and personal details were kept in 
locked cabinets accessible  by the  project supervisor and 
principal investigator of the respective country. All tablets 
and computers were password protected with a secured cen-
tral server system to archive data. The study was approved 
by the Bangladesh Institute of Child Health Ethical Review 
Committee, Nepal Health Research Council Ethical Review 
Board Approval, Ethical Review Committee of Aga Khan 
University and National Bioethics Committee of Pakistan, 
and Stanford University. This project was approved by the 
Centers for Disease Control and Prevention’s human subjects 
review as “research with CDC not directly engaged,” so a full 
IRB approval was not needed.
RESULTS
A total of 8,705 culture confirmed enteric fever cases were en-
rolled from the SEAP sites in all three countries: 4,873 (56%) 
from Bangladesh, 1,602 (18%) from Nepal, and 2,230 (26%) 
from Pakistan. Of these, 7,591 (87%) were S. Typhi and 1, 
114 (13%) were S. Paratyphi. (Table  1). Among the 1,095 S. 
Paratyphi isolates for which drug resistance testing results were 
available, only 3 (.3%), all from Pakistan, were MDR (Table 1). 
Among the 7,491 S. Typhi isolates that had susceptibility 
testing, 1,051 (14%) were MDR: 17% of isolates in Bangladesh, 
1% of isolates in Nepal, and 16% in Pakistan. Among 7,098 S. 
Typhi isolates tested, 1,319 (19%) were XDR. All XDR isolates 
were from Pakistan; 64% of all S. Typhi isolates in Pakistan were 
XDR (Table 1).
Resistance of S. Typhi isolates to first-line antibiotics (ampi-
cillin, cotrimoxazole, and chloramphenicol) varied by country, 
ranging from 18%–27% in Bangladesh, 2%–3% in Nepal, and 
82% in Pakistan (Table 2). Ceftriaxone resistance was found in 
65% of S. Typhi isolates in Pakistan, but none among isolates in 
Bangladesh or Nepal.
FQ non-susceptibility in S. Typhi was very high in all three 
countries (98% in Bangladesh, 87% in Nepal, and 96% in 
Pakistan), and non-susceptibility to azithromycin was detected 
in 77 (2%) isolates in Bangladesh, 9 (.66%) in Nepal and 9 
(.58%) in Pakistan. (Table 2, Figure 2).
Trends in S. Typhi resistance over time varied by country. 
The proportion of enteric fever cases with MDR isolates was 
relatively stable over time in Bangladesh (about 15%–20% of 
all isolates per month), with fewer MDR isolates found in late 
2018 and toward the end of the surveillance period in 2019 
(Figure  1). In Nepal, there were almost no MDR isolates ex-
cept for a 5-month period during November 2018–March 2019. 
(Figure 1).
FQ non-susceptibility among the patients with S. Typhi was 
generally uniform in all three countries during the study period 
except for a decrease in Nepal during November 2018–April 
2019 (Figure 2).
In Pakistan, there was an increasing trend of XDR iso-
lates among the patients with S. Typhi during 2016–2019 
(Figure  3). Complications of severe enteric fever, such as 
hepatitis, hemodynamic shock, pulmonary complications, 
gastrointestinal complications, intestinal perforation and 
sepsis occurred more frequently among patients with XDR/
MDR S. Typhi compared with  non-XDR/MDR S. Typhi cases 
(Table 3). However, the proportion of complications reported 
were infrequent in both groups. Only the occurrence of one 
or more complications was higher in the MDR/XDR ty-
phoid group and statistically significant when compared with 
S. Typhi non-MDR/ XDR cases.
DISCUSSION
This study reported the antimicrobial resistance pattern 
from tertiary care hospitals and laboratory networks from 
three endemic countries, Bangladesh, Nepal, and Pakistan. 
Surveillance for antimicrobial resistance among enteric fever 
isolates from SEAP project revealed high rates of antimicrobial 
non-susceptibility among S. Typhi isolates to FQ in all three 
countries and high rates of XDR S. Typhi in Pakistan. Among 
patients with S. Paratyphi, MDR was currently low and only 
seen in Pakistan. Given the paucity of available antimicrobials, 
the potentially emerging azithromycin non-susceptibility in 
these three countries is a threat for typhoid treatment in en-
demic countries.
MDR in S. Typhi has increased, while in S. Paratyphi it 
has decreased markedly [27]. Previous data from Pakistan 
suggest the prevalence of MDR S. Typhi increased from 
20% in 1992 to approximately 50% in 2015, whereas the 
MDR in S. Paratyphi has declined since 2004 to almost 
negligible levels. In Pakistan, most MDR S. Typhi have 
acquired additional resistance to beta-lactams and FQ, 







ent_3/S276/6013562 by Aga Khan U
niversity, H
ealth Sciences Library user on 26 January 2021

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































ent_3/S276/6013562 by Aga Khan U
niversity, H
ealth Sciences Library user on 26 January 2021
S280 • cid 2020:71 (Suppl 3) • Qamar et al
with Pakistan, where high rates of XDR are reported, the 
proportion of MDR in Bangladesh and Nepal was low [21, 
28].
The epidemics of MDR typhoid in several countries in 
the 1980s and 1990s were the driving force for making 
ciprofloxacin the drug of choice for the treatment of typhoid 
[22, 24, 25]. Fluoroquinolone non-susceptibility in S. Typhi 
started rising in 2002 and reached 96.5% globally in 2015 [15, 
27]. Fluoroquinolones are not only extensively prescribed 
for humans but are widespread in animal husbandry. Sale of 
fluoroquinolones is generally unregulated in developing coun-
tries [29–31]. In low   and middle-income countries, patients 
may not have access to or are prevented from attending health 
facilities due to high out of pocket costs; therefore,  they seek 
treatment over the counter from community pharmacies or in 
the informal sector [32]. In general, a  direct relationship has 
been found between the amount of antibiotic used and the fre-
quency of non-susceptibility to multiple antibiotics [33]. The 
progressive appearance of non-susceptibility against fluoro-
quinolone made third-generation cephalosporins (ceftriaxone 
and cefixime) the treatment of choice for typhoid in endemic 
countries [34, 35]. Now, with the emergence of XDR typhoid 
in Pakistan, treatment options for typhoid are limited to 
azithromycin and carbapenems [18].
Azithromycin is the only oral antibiotic remaining for 
treatment for patients with XDR typhoid. The potential emer-
gence of azithromycin non-susceptibility is an added threat; if 
acquired by the XDR strain of S. Typhi, typhoid may become 
virtually untreatable in outpatients. If antibiotics continue to 
be used as compensation for poor water and sanitation and 
Table 2. Distribution of Antimicrobial Resistance Among Culture 
Confirmed Enteric Fever Patients - Bangladesh, Nepal and Pakistan, 
September 2016–September 2019
Countries
Bangladesh Nepal Pakistan Total
n = 4131 n = 1367 n = 2093 n = 7591
S. Typhi % % % %
Ampicillin
 Resistant 27.31 2.97 82.50 38.33
 Sensitive 72.69 97.03 17.50 61.67
Cotrimoxazole
 Resistant 18.11 2.15 82.08 33.04
 Sensitive 81.89 97.85 17.92 66.96
Chloramphenicol
 Resistant 18.84 1.93 81.50 33.25
 Sensitive 81.16 98.07 18.50 66.75
Ceftriaxone
 Resistant .00 .21 65.25 19.22
 Sensitive 100.00 99.79 34.75 80.78
Ciprofloxacin
 Resistant/Intermediate 97.74 86.77 95.06 95.02
 Sensitive 2.26 13.23 4.94 4.98
Azithromycin
 Resistant 1.89 .67 .59 1.37
 Sensitive 98.11 99.33 99.41 98.63








ent_3/S276/6013562 by Aga Khan U
niversity, H
ealth Sciences Library user on 26 January 2021
AMR in Typhoidal Salmonella in Asia • cid 2020:71 (Suppl 3) • S281
Figure 2. Trend in proportion of S. Typhi isolates with fluoroquinolone non-susceptibility - Bangladesh, Nepal and Pakistan, September 2016–September 2019, Bangladesh, 
Nepal, and Pakistan. Abbreviation: FQ, fluoroquinolone.
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weak health systems, the battle against typhoid will be lost 
[33]. The emergence of non-susceptibility among the com-
monly used antibiotics for typhoid has been associated with 
a worse clinical response, higher rates of complications and 
deaths, as well as prolonged fecal shedding, which sustains 
transmission and propagates secondary cases within commu-
nities [36–38].
In Asia, and more recently in Africa, children with MDR 
typhoid have been reported to be sicker and more toxic at 
admission compared to patients with S. Typhi sensitive to 
antimicrobials. Drug resistant typhoid   leads to high rates of 
complications, prolonged hospital stays, increased treatment 
costs, and subsequent higher risk of mortality [39, 40]. Longley 
et al paper in this supplement.
One way of addressing the issue of antimicrobial resist-
ance may be through the use of TCV [41]. In Bangladesh and 
Pakistan, the high number of cases aged <15 years has impli-
cations for policy decisions for a typhoid vaccination strategy. 
Yousafzai et al paper in this supplement. The choice of routine 
immunization at 9 months versus a onetime catch-up campaign 
in children 9 months–15 years, followed by routine introduc-
tion, would vary depending on the disease burden, disease se-
verity (hospitalizations and deaths), treatment, and intervention 
costs in these countries [42]. In the presence of high disease 
burden in children with high rates of AMR, a onetime catch-up 
campaign followed by routine introduction might be a cost-ef-
fective vaccination strategy in these settings [17, 43].
The rise in AMR in enteric fever in high disease burden 
countries, particularly the increase in XDR typhoid, is also a 
global security concern. Reported cases of imported XDR ty-
phoid among travelers from Pakistan highlight the need for 
coordinated global actions for effective surveillance, improve-
ments in water and sanitation, and implementation of effective 
vaccines [44]. TCV has the potential to be an effective tool to 
fight against all S. Typhi, irrespective of AMR status [45].
Better diagnostics for typhoid are needed, since, for every one 
true case of typhoid fever, 3 to 25 patients without typhoid are 
treated with antimicrobials leading to overuse and misuse of 
antimicrobials [46]. The paucity of microbiology facilities and 
the consequent lack of antimicrobial susceptibility testing data 
to inform empirical antimicrobial treatment have ramifications 
beyond enteric fever. There is a need for low cost, sensitive diag-
nostics for typhoid and paratyphoid that can be made widely 
available to facilitate in typhoid management and control. 
Blood culture, which is the existing “gold standard” has limi-
tations of sensitivity, costs, trainings and quality control [47]. 
This study included blood culture surveillance, but many en-
teric fever endemic areas lack routine blood culture surveillance 
in the absence of special studies.
This study had several strengths. The use of a standard case 
definition and the identification of culture-confirmed enteric 
fever cases, limited misclassification and linked clinical data 
to AMR data. The data for this study were collected prospec-
tively over three years, hence the seasonal trends inferred are 
likely reliable. Limitations of the study included collection of 
complications  data from medical charts, which could have 
underestimated the scope. Additionally, we were not able to 
characterize the azithromycin isolates by genotyping to assess 
if there were any differences in molecular patterns of non-
susceptibility by site from the three countries. Furthermore, 
though there is no comparative evaluation of blood culture 
sensitivity between drug sensitive and MDR enteric fever in-
fections to indicate a reduced sensitivity of blood cultures 
in MDR or XDR typhoid, one study on quantitation of S. 
Typhi in blood in a Vietnamese cohort indicated that bac-
terial counts were higher in patients with drug  resistant ty-
phoid fever [48]. It is therefore possible that AMR might have 
affected the sensitivity of blood culture in the SEAP study 
population.
CONCLUSION
The rise in FQ non-susceptibility, the emergence of XDR S. 
Typhi, and the potential for azithromycin non-susceptibility is 
Table 3. Complications Between Drug Resistant and Sensitive Cases of 




S. Typhi (non 
MDR/ XDR 
Cases)
Pvaluen = 1650 % n = 443 %
Hepatitis 20 1.2 1 .2 .1
Hemodynamic shock 13 .8 0 0 .083
Pulmonary complications 10 .6 0 0 .13
GI complication 9 .6 0 0 .22
Intestinal perforation 8 .5 0 0 .22
Sepsis 6 .4 0 0 .35
Intestinal obstruction 6 .4 1 .2 1
Encephalopathy 3 .2 2 .5 .29
Renal impairment 2 .1 0 0 1
Blood cell disorders 2 .1 0 0 1
Others (myocarditis/wound infection/
disseminated intravascular coagu-
lation (DIC) /musculoskeletal com-
plications/electrolyte imbalance)
4 .2 0 0 .58
 At least one or more than one com-
plications iIndividuals)
58 3.5 4 .90 .005
All Admissionsa n = 710  
mean (SD)
n = 145  
mean (SD)
 
Duration/Days of hospitalization 9.98 (7.87) 10.43 (10.61) .555
Temperature at admissionb 101.45 (1.63) 101.18 (1.89) .109
aAll admissions includes patients recruited at OPD, IPD, Hospital Lab, Surgical.
bTemperature at admission: S. Typhi (MDR/XDR Cases) n = 687/710, information not avail-
able n = 23. S. Typhi (non MDR/ XDR Cases) n = 144/145, information not available n = 1.
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a warning sign for the global community to expedite efforts for 
the control of enteric fever. The results from this study provide 
an important database on the antimicrobial resistance patterns 
among S. Typhi isolates in Bangladesh, Nepal, and Pakistan, 
for comparison across and within these three countries. 
Additionally, the data can be used as an important baseline 
measurement of AMR before the introduction of TCV in rou-
tine immunization programs in these three countries. Although 
the potential for identifying new drugs for enteric fever is not 
encouraging, the routine surveillance of AMR is still critical to 
assess the effectiveness of antimicrobial regimens and to guide 
local and national treatment policies.
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